Autres langues Bioxyne Limited

Actions

BXN

AU000000BXN6

Marché Fermé - Australian S.E. Autres places de cotation 07:31:42 01/05/2024			Varia. 5j.	Varia. 1 janv.
0,006 ^AUD	0,00%		-25,00%	-45,45%

29/02	Bioxyne Limited annonce ses résultats pour le semestre clos le 31 décembre 2023	CI
05/02	Bioxyne reçoit une licence pour fabriquer du cannabis médical et de la MDMA ; les actions grimpent de 50%.	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Bioxyne to Raise AU$1.45 Million via Share Issuance	18/04
Bioxyne Limited Reports Earnings Results for the Half Year Ended December 31, 2023	29/02
Bioxyne Receives License to Manufacture Medical Cannabis, MDMA; Shares Up 50%	05/02
Bioxyne Limited Announces Retirement of N H Chua as Director	17/11
Bioxyne Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/08/23
Bioxyne Unit Joins Forces to Launch B2B Cannabis Trading Platform in Australia; Shares Slump 11%	15/08/23
Bioxyne Limited Extends Amazon Footprint into US and Japan	17/07/23
Australian Shares Track Gains of Wall Street Peers Ahead of Inflation Data, Policy Meetings	13/06/23
Bioxyne Launches Online Healthcare with Technology Partner InstantScripts; Shares Decline 8%	13/06/23
Bioxyne Limited Appoints Jason Hine as Director	23/05/23
Bioxyne Acquires Breathe Life Sciences	22/05/23
Bioxyne Limited acquired Breathe Life Sciences Pty Ltd.	19/05/23
Bioxyne Proceeds With Breathe Life Sciences Acquisition; Shares Fall 4%	20/03/23
Bioxyne Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23/02/23
Bioxyne's Fiscal H1 Revenue Declines	27/01/23
Bioxyne to Acquire Health, Wellness Peer Breathe Life Sciences; Shares Gain 4%	19/12/22
Bioxyne Limited entered into a binding term Sheet to acquire Breathe Life Sciences Pty Ltd for AUD 32 million.	19/12/22
Bioxyne Limited Announces Joining of Mr. Sam Watson the Board as Joint Chief Executive Officer	18/12/22
Bioxyne Sells 49% Stake in Direct Selling Business	24/10/22
Paramount Star Investments Limited reached agreement to acquire 49% of Direct Selling Business of Bioxyne Limited from Bioxyne Limited for $1 million.	24/10/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Bioxyne Limited

Actions

BXN

AU000000BXN6

Autres langues

Filtres